One post from Mindy Pelz's dossier. This page reviews a single piece of material. The full dossier carries the verified credential and scope verdicts.
Read the full dossier →https://web.archive.org/web/20250802163749/https://www.richroll.com/podcast/mindy-pelz-926/
View dossier →Mindy Pelz alias The Alzheimer’s Solutionist
Website · richroll.com#ayesha-sherzai
Practice location
11370 Anderson St Ste B-100
Loma Linda, CA 92354
Funnel-first framing that runs on persuasion, light on published evidence.
- Of 13 health claims, 4 run counter to or conflict with the published evidence, and 6 were not independently checked.
- Primary persuasion tactic: Credential-heavy prevention promise.
- Stated credentials look inflated relative to the advice given.
- Profits from the products and labs they recommend.
- Gives advice beyond what their license covers.
Ayesha Sherzai arrives with an MD, a neurology fellowship, and a five-part brain-health formula marketed with the confidence of a cure-adjacent master key. The pitch is elegantly packaged: make Alzheimer’s terrifying, make conventional medicine the failed villain, then let the starred book link collect a little Amazon confetti.
High grift signals
Score breakdown
Direct answer
Dr. Trust Me Bro analyzed Mindy Pelz's claim that "Team Sherzai’s 5-part program can prevent Alzheimer’s disease and reverse symptomology." using transcript and metadata cross-checked against academic sources. Peer-reviewed literature indicates the claim is only partially supported: There is no established pharmaceutical or surgical treatment that prevents, reverses, or cures established Alzheimer’s disease. Conventional symptomatic drugs such as cholinesterase inhibitors and memantine provide modest benefits and do not modify disease progression. Several anti-amyloid drug candidates have failed in trials, as reflected by reports of failed plaque-targeting candidates . Evidence that treating vascular risk factors prevents Alzheimer’s disease is inconsistent; a systematic review found no significant effect of blood-pressure lowering on Alzheimer’s incidence , and a multidomain vascular-care trial found no reduction in dementia incidence . [1][4] The claim is too absolute because effective pharmaceutical treatments now exist that modestly slow progression in selected patients with early, biomarker-confirmed Alzheimer’s disease. Lecanemab and donanemab are FDA-approved anti-amyloid therapies for mild cognitive impairment or mild dementia due to Alzheimer’s disease, and reviews describe them as slowing cognitive and functional decline rather than merely treating symptoms . [3] The treatment landscape review likewise identifies lecanemab and donanemab as approved disease-modifying therapies for early Alzheimer’s disease . [2] However, these therapies do not reverse established disease, do not cure it, are not indicated for moderate or severe disease, require specialized monitoring, and carry risks including amyloid-related imaging abnormalities. Evidence for prevention remains uncertain: a systematic review found that vascular-risk-factor treatment might reduce dementia or Alzheimer’s risk in observational studies but called for further trials . The index list also includes evidence that solanezumab was considered potentially disease-modifying , but this does not establish a clinically effective approved treatment and should not be treated as proof of prevention or reversal. Western medicine has not failed entirely, but its achievements are limited. Standard drugs can provide symptomatic benefit, and anti-amyloid monoclonal antibodies can produce a statistically significant but modest slowing of decline in carefully selected people with early Alzheimer’s disease . No pharmaceutical or surgical treatment reliably reverses or cures Alzheimer’s disease, and no drug is established for broad primary prevention of Alzheimer’s disease. Therefore, the claim is inaccurate because it denies the existence of approved disease-modifying drugs, while its statements about the absence of reversal, cure, and proven broad prevention are broadly consistent with mainstream medical evidence. Often searched as Dr Mindy Pelz.
Key findings
- False Authority: The copy invokes neurologist credentials and claims of rigorous science to present unusually large prevention estimates as settled fact, without showing the study design, endpoints, or limitations on this page.see section ↓
- Claim "Western medicine has failed to combat Alzheimer’s disease and has no effective pharmaceut…": only partially supported.see section ↓
- Claim "Lifestyle changes can delay Alzheimer’s disease by ten to fifteen years in people with st…": not supported by peer-reviewed evidence.see section ↓
- Mindy Pelz shows credential inflation relative to stated vs likely credentials.see section ↓
- Against State Medical Board scope rules, these advertised activities appear outside Mindy Pelz's license: Ninety percent of Alzheimer’s cases can be prevented., Lifestyle changes can delay Alzheimer’s disease by ten to fifteen years in people with strong genetic risk., Western medicine has failed…see section ↓
- 3 of 14 advertised activities assessed against board scope rules.see section ↓
- Claim "Team Sherzai’s 5-part program can prevent Alzheimer’s disease and reverse symptomology.": not supported by peer-reviewed evidence.see section ↓
- Claim "Diets high in meat unequivocally contribute to cognitive decline.": only partially supported.see section ↓
Claims & evidence
3 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
Mindy Pelz is not licensed or approved by State Medical Board to advertise Ninety percent of Alzheimer’s cases can be prevented. as within their scope of practice.
Ninety percent of Alzheimer’s cases can be prevented.
- Supports
- Some dementia risk is associated with modifiable factors, and prevention or delay is considered possible through population-level and individual interventions. [1][4] The 2024 Lancet Commission estimated that addressing 14 modifiable risk factors could potentially prevent or delay about 45% of dementia cases, not 90%. [2] WHO guidelines support risk-reduction strategies such as physical activity, tobacco cessation, healthy diet, and management of hypertension, diabetes, obesity, hearing loss, and other conditions, while noting important evidence gaps. [3]
- Contradicts
- The claim substantially overstates the best available estimate: approximately 45% of dementia cases, rather than 90%, are estimated to be potentially preventable or delayable under the Lancet Commission's assumptions. [2][3][4] The cited index records are ClinicalTrials. gov studies involving glycemic monitoring, rheumatoid arthritis exercise, angioplasty, medical education, heart failure, noncommunicable-disease care, training, and neck pain; none directly evaluates prevention of Alzheimer disease or supports a 90% prevention estimate. [1]
- Mainstream view
- Alzheimer disease and dementia risk can likely be reduced, and some cases may be delayed, through lifelong management of modifiable risks. [1][2][3][4] However, prevention is not guaranteed, many risk-factor estimates are population-attributable and assumption-dependent, and genetic, age-related, and other nonmodifiable factors remain. There is no high-quality evidence that 90% of Alzheimer disease cases can be prevented.
“90% of all Alzheimer’s cases can be prevented.”
See every doc bro advertising Dementia and Alzheimer disease
Mindy Pelz is not licensed or approved by State Medical Board to advertise Lifestyle changes can delay Alzheimer’s disease by ten to fifteen years in people with strong genetic risk. as within their scope of practice.
Lifestyle changes can delay Alzheimer’s disease by ten to fifteen years in people with strong genetic risk.
- Supports
- Multidomain lifestyle interventions involving diet, exercise, cognitive training, and vascular-risk management can improve cognitive outcomes in older adults at risk for dementia, including APOE ε4 carriers, although the FINGER subgroup analysis did not find a statistically significant difference in intervention effects by APOE status . [5][6][7] Reviews conclude that dementia risk factors are potentially modifiable irrespective of APOE genotype, and the 2024 Lancet Commission estimated that addressing multiple risk factors could delay or prevent a substantial proportion of dementia cases, but this is a population-level estimate rather than proof of a 10-to-15-year delay in genetically high-risk individuals . [8]
- Contradicts
- No cited paper or high-quality direct evidence establishes that lifestyle changes delay Alzheimer’s disease itself by 10 to 15 years in people with strong genetic risk. The FINGER randomized-trial subgroup analysis found cognitive benefits but no significant APOE-by-intervention interaction, and it did not measure a 10-to-15-year delay in Alzheimer’s onset . [6][7] Observational estimates of longer cognitively healthy life expectancy are substantially smaller than 10 to 15 years; one reported estimate was approximately 4. 8 years in men and 5. 3 years in women for those with four to five healthy lifestyle factors, across APOE genotypes . [5][8] Evidence that lifestyle effects differ specifically in APOE4 carriers remains inconclusive, with only a minority of trials directly testing this interaction .
- Mainstream view
- Healthy lifestyle measures are recommended because they are associated with lower dementia risk and may preserve cognition in people with APOE-related susceptibility. [5][6][7][8] However, genetic risk is not eliminated, and evidence supports risk reduction or modest delay at the population level—not a proven 10-to-15-year postponement of Alzheimer’s disease in strongly genetically predisposed people. The claim substantially overstates the certainty and magnitude of the evidence.
“for the 10% with a strong genetic risk for cognitive decline, the disease can be delayed for ten to fifteen years.”
See every doc bro advertising Dementia and Alzheimer disease
Mindy Pelz is not licensed or approved by State Medical Board to advertise Western medicine has failed to combat Alzheimer’s disease and has no effective pharmaceutical or surgical treatment to prevent or reverse it. as within their scope of practice.
Western medicine has failed to combat Alzheimer’s disease and has no effective pharmaceutical or surgical treatment to prevent or reverse it.
- Supports
- There is no established pharmaceutical or surgical treatment that prevents, reverses, or cures established Alzheimer’s disease. [10][11] Conventional symptomatic drugs such as cholinesterase inhibitors and memantine provide modest benefits and do not modify disease progression. Several anti-amyloid drug candidates have failed in trials, as reflected by reports of failed plaque-targeting candidates . Evidence that treating vascular risk factors prevents Alzheimer’s disease is inconsistent; a systematic review found no significant effect of blood-pressure lowering on Alzheimer’s incidence , and a multidomain vascular-care trial found no reduction in dementia incidence . [9][12]
- Contradicts
- The claim is too absolute because effective pharmaceutical treatments now exist that modestly slow progression in selected patients with early, biomarker-confirmed Alzheimer’s disease. Lecanemab and donanemab are FDA-approved anti-amyloid therapies for mild cognitive impairment or mild dementia due to Alzheimer’s disease, and reviews describe them as slowing cognitive and functional decline rather than merely treating symptoms . [11] The treatment landscape review likewise identifies lecanemab and donanemab as approved disease-modifying therapies for early Alzheimer’s disease . [10] However, these therapies do not reverse established disease, do not cure it, are not indicated for moderate or severe disease, require specialized monitoring, and carry risks including amyloid-related imaging abnormalities. Evidence for prevention remains uncertain: a systematic review found that vascular-risk-factor treatment might reduce dementia or Alzheimer’s risk in observational studies but called for further trials . [9][12] The index list also includes evidence that solanezumab was considered potentially disease-modifying , but this does not establish a clinically effective approved treatment and should not be treated as proof of prevention or reversal.
- Mainstream view
- Western medicine has not failed entirely, but its achievements are limited. Standard drugs can provide symptomatic benefit, and anti-amyloid monoclonal antibodies can produce a statistically significant but modest slowing of decline in carefully selected people with early Alzheimer’s disease . [11] No pharmaceutical or surgical treatment reliably reverses or cures Alzheimer’s disease, and no drug is established for broad primary prevention of Alzheimer’s disease. [9][10] Therefore, the claim is inaccurate because it denies the existence of approved disease-modifying drugs, while its statements about the absence of reversal, cure, and proven broad prevention are broadly consistent with mainstream medical evidence.
“The sad truth is that Alzheimer’s is a condition that Western medicine has utterly failed to combat, let alone cure. Simply put, there is no pharmaceutical or surgical treatment to effectively prevent or reverse this savage and cataclysmic condition.”
See every doc bro advertising Dementia and Alzheimer disease
Manipulation
transcript · cited
The copy invokes neurologist credentials and claims of rigorous science to present unusually large prevention estimates as settled fact, without showing the study design, endpoints, or limitations on this page. Likely motive: Convert professional credentials and research branding into trust for a proprietary lifestyle framework.
“These are not estimates. Nor are they wishful thinking. They are conclusions based on rigorous science performed by neurologists Drs. Dean and Ayesha Sherzai.”
transcript · cited
The page intensifies fear and helplessness around a serious disease before presenting its program as the hopeful solution. Likely motive: Increase emotional receptivity to the Team Sherzai message, books, programs, and related commercial content.
“you know first hand the devastation it creates. You’ve seen it’s ravaging effects. Perhaps you’ve even shouldered the immense emotional, financial and social burden it produces — and the hopelessness it provokes.”
transcript · cited
A precise, dramatic estimate is presented as a conclusion rather than a context-dependent population-attributable-risk interpretation. It does not establish that an individual can prevent Alzheimer’s by following this program. Likely motive: Create a memorable, high-conversion promise around a preventable disease narrative.
“90% of all Alzheimer’s cases can be prevented.”
transcript · cited
Media references, prominent guests, and professional titles are clustered to provide social proof around claims that still require independent evidence review. Likely motive: Borrow authority from media outlets, guests, and other clinicians to strengthen the brand.
“The Times: Do this couple have the cure for Alzheimer’s disease?”
transcript · cited
The central Alzheimer’s narrative is paired with a starred book link and an affiliate disclosure, turning disease education into a monetizable recommendation funnel. Likely motive: Generate affiliate revenue and book demand from a high-anxiety health topic.
“The Alzheimer’s Solution*”
Commerce & grift map
The apparent money flow is Alzheimer’s fear and prevention messaging to an affiliated book recommendation, with Amazon paying a qualifying-purchase commission. The disclosed affiliate link is a conflict, but the supplied material does not establish a supplement-plus-lab funnel, referral fee, or dispensing markup.
Amazon
Commerce
Amazon Associates pays the referring site a qualifying-purchase commission through tracked links. Vendor page language: "Earn Commissions.Sign up Amazon Associates - Amazon’s affiliate marketing program Welcome to one of the largest affiliate marketing programs in the world."
Doc Bro outbound link (live) · Archive pending
Vendor provider compensation page (live) · Archive pending
Vendor language on provider benefit
- “Earn Commissions.Sign up Amazon Associates - Amazon’s affiliate marketing program Welcome to one of the largest affiliate marketing programs in the world.”
- “Earn Commissions.Sign up Operating agreement Program policies Conditions of use Contact us © 1996-2025, Amazon.com, Inc.”
How the money flows
- Affiliate / promo link The practice links starred books, including The Alzheimer’s Solution, through Amazon affiliate links and states that it earns fees from qualifying purchases. “Books and products denoted with an asterisk are hyperlinked to an affiliate program.”
“Books and products denoted with an asterisk are hyperlinked to an affiliate program.”
Store links detected
- The Alzheimer’s Solution*High likelihood
“Amazon affiliate tag and link parameters”
- Fast Like a GirlHigh likelihood
“Amazon tracking parameters detected”
- The Menopause ResetHigh likelihood
“Amazon tracking parameters detected”
- Eat Like a GirlHigh likelihood
“Affiliate program language on page”
- The Book of Joy*High likelihood
“Amazon affiliate tag and link parameters”
- Body Wise*High likelihood
“Amazon affiliate tag and link parameters”
- This Cheese is NutsUnknown
- This Cheese Is Nuts!Unknown
Credentials & scope
Stated: none · Likely: unverified
Ayesha Sherzai is presented as an MD with preventive-medicine and neurology training and a vascular-neurology fellowship. The source supports a real physician degree rather than credential inflation, although the page does not independently verify current licensure, board certification, or completion of the PhD.
Permitted scope vs advertised
State Medical Board · Confidence: low
The practice state and physician identity are not provided, so the applicable state medical board and practice-act language cannot be confirmed. A physician generally holds a broad license to diagnose and treat medical conditions, but these advertising claims must still be evaluated against the physician’s identifiable specialty, professional competence, and mainstream evidence-based standard of care.
3 of 14 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| Ninety percent of Alzheimer’s cases can be prevented. This categorical numerical prevention claim substantially exceeds the available evidence, which supports risk reduction rather than a proven 90-percent prevention rate. | Outside scope |
| Lifestyle changes can delay Alzheimer’s disease by ten to fifteen years in people with strong genetic risk. The specific ten-to-fifteen-year delay is not established as a reliable clinical outcome for genetically high-risk individuals and is presented too definitively. | Outside scope |
| Western medicine has failed to combat Alzheimer’s disease and has no effective pharmaceutical or surgical treatment to prevent or reverse it. The sweeping claim is misleading because evidence-based pharmaceutical treatments and symptomatic therapies exist, even though no established treatment reverses Alzheimer’s disease. | Outside scope |
Sources: The Alzheimer's Solution - MemoryCare, 5 healthy habits that ‘all but guarantee' you won't get Alzheimer's, To Prevent Alzheimer’s, There’s Nothing Like Prevention, Experts Say, The Alzheimer's solution : a breakthrough program to prevent and reverse the symptoms of cognitive decline at every age / Dean Sherzai, M.D., and Ayesha Sherzai, M.D.
Scope comparison mirror
Side-by-side view of the archived marketing homepage and what a Physician (MD/DO) scope permits near Loma Linda, CA. Open the mirror for the full comparison: archive on the left, permitted scope and licensed-care paths on the right.
Mirror generated 2026-08-26 18:00 UTC. The archive pane loads styles and images from the intake snapshot.
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission TKTuSPgraCw1DFJtxdhOP
Fight disinformation
Log a public thread where Mindy Pelz is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked Mindy Pelz's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/TKTuSPgraCw1DFJtxdhOP. White-coat charisma isn't evidence.
Full DTMB scan on Mindy Pelz: https://drtrustmebro.com/analyze/TKTuSPgraCw1DFJtxdhOP
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
No conversation links logged yet. Be the first above.
Nudge the Doc Bro
We email a public contact address from their site so Mindy Pelz can review this dossier and dispute anything we got wrong.
Know someone who can help?
If you think someone has firsthand information about Mindy Pelz, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for Mindy Pelz. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: pvJzgDaOsi-cbtDPFqjZB
- Wall entry: /influencer/pvJzgDaOsi-cbtDPFqjZB
- Analysis ID: TKTuSPgraCw1DFJtxdhOP
- Source: https://richroll.com/podcast/mindy-pelz-926?dtmb_roster=ayesha-sherzai
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Dementia prevention, intervention, and care 2024
- [2] Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
- [3] Risk reduction of cognitive decline and dementia: WHO guidelines ...
- [4] Risk reduction of cognitive decline and dementia
- [5] Healthy lifestyle factors outweigh influence of APOE genetic ...
- [6] Effect of the ApoE genotype on the efficacy of multidomain lifestyle interventions on cognitive change: a meta‐analysis of three randomized clinical trials
- [7] APOE ε4 affects cognitive decline but does not block benefits of healthy lifestyle - Nature Reviews Neurology
- [8] Life Course Modifiable Risk Factors for Dementia Stratified by ApoE ...
- [9] Treatment of Cardiovascular Risk Factors to Prevent ...
- [10] A 2025 update on treatment strategies for the Alzheimer's disease ...
- [11] Anti-Amyloid Therapies for Alzheimer's Disease: Progress, Pitfalls ...
- [12] Does Treating Vascular Risk Factors Prevent Dementia ...